Linkedm People v
`
`Keri
`
`Phares
`
`Ken Phares
`Vice President Pharmaceutical Development at United
`Therapeutics Corporation
`Hillsborough, North Carolina
`
`500+ connections
`
`._ United Therapeutics
`Corporation
`[ii] University at North Carolina at
`7 Chapel Hill
`
`a .t‘heit signing ~ you ca” choose to nan we tieriia in plvate lTCde
`
`Activity
`
`,, ONE OF OURS Bo much Courage, bravery & honor in one Picture 5”
`
`- m, httpszfllnkdjnlgMKQaEO W
`
`rotiuiil‘ Liked by Keri Phares
`
`
`I would like to take a moment of reflection to thank my customers and
`vendors. There is a saying somewhere about you are measured by how
`you perform.“
`Liked by Keri Phares
`
`Expedence
`Vice President Pharmaceutical Development
`rm:—
`United Therapeutics Corporation
`Jun 2301, Present 19 years 1i months
`55 T.W Alexander Drive, RiP, NC 27709
`Responsibilities included: pretormulation, formulation development, analytical and
`pioanalytical method development and writing and editing CMC sections ol‘ regulatory
`submissions such as lNDs, CTDs, supplements, amendments, and annual reports.
`Managed: cl
`ical supplies, process scale up, and packaging.
`Specitic activmes include:
`- Coordinated pharmaceutical development activities from API characterization to drug
`product development and process scale up.
`- Analytical activities included characterization of API and drug product along with in- vitro
`testing of the drug product.
`- Bioanalytical activities included managing the analysis 01 samples from toxicology and
`clinical supplies.
`- Manage timelines and worktlow for these activities across various projects.
`Show less "
`
`Adjunct Associate Professor; Eshelman School of Pharmacy
`University of North Carolina at Chapel Hill
` Jan 2019 7 Present 2 years 4 months
`Chapel Hill, NC
`Lectures in advanced pharmaceutics classes
`Senior Scientist
`- Triangle Pharmaceuticals
`May 1999 - Jun 2001 2 years 2 months
`Durham, NC
`Preformulation and formulation of antiviral compounds. The preformulation work involved
`assessing solubility, stability, polymorphism, and excipient compatibility. The formulations
`developed were solid- and liquid-dosage forms.
`Senior Scientist
`3‘ 3M Pharmaceuticals
`May 1996 a May 1999 3 years i month
`Preformulation of compounds lrom the chemistry department at (M pharmaceuticals and
`formulation of compounds selected tor development. Pretormulation work involved assessing
`solubility in various organic and aqueous solvents, stability in the solid state and solution, and
`polymorph screening. Formulation work involved incorporation of new chemical entities into
`solid and semisolid dosage forms to support toxicology and clinical studies. Supervised one
`technician, three 3.5. level and one Ph.D. scientist. Contributed to writing the CMC section of
`one NBA and one lND submission tothe FDA.
`Show less "
`
`Education
`
`University of North Carolina at Chapel Hill
`Post-doc , Pharmaceutical Chemistry
` 1993 71995
`Activities and Societies: Under the guidance of Dr. Cho and working under a grant funded by
`PhRMA studied tolate conjugates to enhance absorption.
`
`University of North Carolina at Chapel Hill
`PhD . Pharmaceutical Chemistry
` 1988 a 1993
`
`People also viewed
`Betsy Eades
`Director, Head of Business
`Development at United
`Therapeutics Corporation
`RaleighrDurnanirCnaoc Hill Area
`Noah Byrd
`Associate Vice Presidenl, Global
`Regulatory Affairs at United
`Therapeutics Corporation
`Durnani, NC
`Mark Battaglia
`Sr Director, Global Data Operations
`at uniteo Therapeutics
`Ralclgh, NC
`Dean Bunce
`eve Global Regulatory Arrairs,
`United Therapeutics
`ADCX, NC
`Kevin Gray
`Vice President, Trade Relations and
`Patient Program Management at
`United Therapeutics
`Ralclgh, NC
`Maria Bailey
`German and Electives Teacherai
`K12 International Academy
`Durham, NC
`Brian Greer, PMP
`Project Engineer at cal Engineering
`in Louisville. Kentucky
`Loulsvillc Mctropolltan Area
`Mitchell Ronaldson
`Field Sunervisor/ Construction
`Management
`British colum oia, Canada
`Jeff. "Lars" Larson
`NMAS
`Clearwotcr, MN
`Jessica Meyer
`Head (it PIOCIHEMSHI all United
`Therapeutics (Purchasing,
`OLIKSOUI'ClHQ 5CDHKFSCIS DlVlSiOflS)
`RaleighrDurnantrCnanc Hill Aron
`Show more profiles v
`
`00W090®®$
`
`Others named Ken Phares
`
`Manager or Patient Nutrition
`SQWICES at WVUMEdlClfle
`. Ken Phares
`United States
`
`Nutrition Manager at WVUH-Ruby
`. Ken Phares
`MEle’lai Hospital
`Morgantown, wv
`Ken Phares
`"SHOWIOOM Auto Detailing
`United States
`
`. Ken Phares
`United States
`
`6 others named Ken Phares are on
`Llnkedln
`
`See others named Keri Phares
`
`Add new skills with these
`courses
`
`Microsoft Cognitive
`Services for Developers:
`2 Speech@
`HTTP Essential Training
`
`
`
`’il‘11
`
`Java EE: Bean Validation
`
`See all courses
`
`Ken's public profile badge
`Include this Linkedln protile on other
`websites
`
`Keri Phares
`. Vice President Pharmaceutical
`Development at United
`Therapeutics Coiporatioh
`VlCC Picstdcnt Phanhnccuiicnl
`m- Development at United Therapeutics
`Cfli'DOi'aUDi'i
`
`|PR2020-OO7
`’
`Chanel Hill
`m Unlvcrsllv or North Caro lna at
`United Therapeutics EX20
`Linkedlitl
`Pa e 1 o
`Cinnaminson High School
`
`.
`
`West Virginia University
`E.S.- Pharmacy
`1980 71985
`
`

`

`‘
`
`Diploma
`1976 71980
`
`Licenses & Certifications
`
`Registered Pharmacist
`_
`
`I
`
`Groups
`Rx&D - Biopharmaceutical, Pharmaceutical and Biotechnology Research and
`, Development
`
`WVU Alumni Triangle Group
`
`rm;
`
`American Association of Pharmaceutical Scientists
`
`_
`
`_
`7.1
`
`Pharmaceutical Discussion Group
`
`H Formulation Research and Development
`
`P Pharma Excipients
`Protein Stability
`
`Show fewer groups A
`
`View Ken's full profile
`CD See who you know in common
`'El Get introduced
`38 Contact Ken directly
`
`Linkedin 1-1
`
`(our
`
`J;
`
`«,2 Jlil'y
`
`L3:
`
`in new:
`
`'1 .zm "u :,
`
`Ecru» lulu.-
`
`w "2-
`
`
`:1
`
`B am Turf.
`
`shims
`
`
`
`Cu“|i'm m. [tililélllir‘
`
`,«ume v
`
`
`
`